|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0017262,
umls-concept:C0034819,
umls-concept:C0085862,
umls-concept:C0185117,
umls-concept:C0348016,
umls-concept:C0443315,
umls-concept:C1299583,
umls-concept:C1335268,
umls-concept:C1419030,
umls-concept:C1420280,
umls-concept:C1515139,
umls-concept:C1522405,
umls-concept:C1549571,
umls-concept:C1608386,
umls-concept:C2911684
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1994-11-10
|
|
pubmed:abstractText |
The effects of immunotherapy with recombinant interleukin-2 (rIL-2) on peripheral blood lymphocytes have been a matter of debate. In this study the authors addressed the issue of the biologic effects of two different schedules of rIL-2 administration (i.e., continuous intravenous infusion versus subcutaneous injection) on the expression of the p55 and p75 chains of interleukin-2 receptor (IL-2R).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD56,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
74
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2562-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7522954-Acute Disease,
pubmed-meshheading:7522954-Adolescent,
pubmed-meshheading:7522954-Adult,
pubmed-meshheading:7522954-Aged,
pubmed-meshheading:7522954-Antigens, CD,
pubmed-meshheading:7522954-Antigens, CD3,
pubmed-meshheading:7522954-Antigens, CD56,
pubmed-meshheading:7522954-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:7522954-Child,
pubmed-meshheading:7522954-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:7522954-Humans,
pubmed-meshheading:7522954-Immunologic Factors,
pubmed-meshheading:7522954-Immunophenotyping,
pubmed-meshheading:7522954-Infusions, Intravenous,
pubmed-meshheading:7522954-Injections, Subcutaneous,
pubmed-meshheading:7522954-Interleukin-2,
pubmed-meshheading:7522954-Kidney Neoplasms,
pubmed-meshheading:7522954-Killer Cells, Natural,
pubmed-meshheading:7522954-Leukemia,
pubmed-meshheading:7522954-Middle Aged,
pubmed-meshheading:7522954-Receptors, Interleukin-2,
pubmed-meshheading:7522954-Recombinant Proteins,
pubmed-meshheading:7522954-T-Lymphocytes
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
|
|
pubmed:affiliation |
Padua University School of Medicine, Department of Clinical Medicine, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
